Thomas F. Gajewski to Carcinoma, Renal Cell
This is a "connection" page, showing publications Thomas F. Gajewski has written about Carcinoma, Renal Cell.
Connection Strength
0.561
-
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004 Jul; 15(7):1109-14.
Score: 0.174
-
Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells. Bone Marrow Transplant. 2004 Mar; 33(5):491-7.
Score: 0.170
-
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006 Jul 15; 119(2):317-27.
Score: 0.050
-
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9.
Score: 0.049
-
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 2005 Feb; 35(3):253-60.
Score: 0.045
-
Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother. 2002 May-Jun; 25(3):269-77.
Score: 0.037
-
Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J Urol. 2001 Apr; 165(4):1208-9.
Score: 0.035